ArticleFrontiers in immunology2020
Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Review
- Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study.Therapeutic advances in neurological disorders · 2025Article
- Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.Frontiers in immunology · 2023Article
- Influence of exercise on quantity and deformability of immune cells in multiple sclerosis.Frontiers in neurology · 2023Article
- Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity.Acta neuropathologica · 2022Article
- Peripheral B-cell dysregulation is associated with relapse after long-term quiescence in patients with multiple sclerosis.Immunology and cell biology · 2022Article
- Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up.Frontiers in immunology · 2022Article
- Loss of thymic function promotes EAE relapse in anti-CD52-treated mice.Current research in immunology · 2022Article
- Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.Current neuropharmacology · 2022Article
- Review
- Article
- Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.Multiple sclerosis and related disorders · 2021Article
- Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.Journal of neurology, neurosurgery, and psychiatry · 2021Article
- Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study.Frontiers in neurology · 2021Article
- Encephalitogenic and Regulatory CD8 T Cells in Multiple Sclerosis and Its Animal Models.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.Annals of clinical and translational neurology · 2020Article
- COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.Clinical and experimental immunology · 2020Review
- The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.Multiple sclerosis and related disorders · 2020Review
- Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy.BMC neurology · 2020Article
- New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.